222 related articles for article (PubMed ID: 33028766)
1. Obstructive Jaundice Due to Duodenal Ulcer Induced by Lenvatinib Therapy for Hepatocellular Carcinoma.
Suoh M; Hagihara A; Yamamura M; Maruyama H; Taira K; Enomoto M; Tamori A; Fujiwara Y; Kawada N
Intern Med; 2021 Feb; 60(4):545-552. PubMed ID: 33028766
[TBL] [Abstract][Full Text] [Related]
2. Colitis induced by Lenvatinib in a patient with advanced hepatocellular carcinoma.
Miyajima S; Tsuji K; Kito Y; Yoshida N; Matsunaga K; Tsuji S; Katayanagi K; Yonezawa M; Kubo A; Ushijima K; Minato H; Doyama H
Clin J Gastroenterol; 2021 Feb; 14(1):187-192. PubMed ID: 33025343
[TBL] [Abstract][Full Text] [Related]
3. Lenvatinib-induced acute acalculous cholecystitis in a patient with hepatocellular carcinoma.
Ishigaki K; Hamada T; Nakai Y; Ishigaki Y; Oyama H; Kanai S; Suzuki T; Nakamura T; Sato T; Hakuta R; Saito K; Saito T; Takahara N; Mizuno S; Kogure H; Tateishi R; Tada M; Koike K
Clin J Gastroenterol; 2020 Aug; 13(4):568-571. PubMed ID: 32242306
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib-induced Interstitial Pneumonia in a Patient with Hepatocellular Carcinoma.
Imakura T; Sato S; Tomonari T; Murakami K; Takahashi N; Naito N; Mima M; Kagawa K; Koyama K; Nishimura H; Kawano H; Nokihara H; Azuma M; Takayama T; Nishioka Y
Intern Med; 2022 Apr; 61(8):1211-1217. PubMed ID: 34544944
[TBL] [Abstract][Full Text] [Related]
5. Lenvatinib-induced tumor lysis syndrome in a patient with advanced hepatocellular carcinoma: a case report.
Shimizu Y; Sunagozaka H; Yamagata K; Hirai H; Miura M; Yonemoto Y; Naito Y; Hasatani K; Yoshikawa J; Aoyagi H; Kaneko S
Clin J Gastroenterol; 2021 Apr; 14(2):645-649. PubMed ID: 33389590
[TBL] [Abstract][Full Text] [Related]
6. Repeated Perforation of the Gallbladder in a Patient with Hepatocellular Carcinoma Receiving Lenvatinib.
Honda S; Saito Y; Sawada K; Hasebe T; Nakajima S; Okumura T
Intern Med; 2020 Mar; 59(5):657-662. PubMed ID: 31735795
[TBL] [Abstract][Full Text] [Related]
7. Partial Splenic Embolization for Lenvatinib Therapy-associated Thrombocytopenia Among Patients With Hepatocellular Carcinoma.
Sato N; Beppu T; Kinoshita K; Yuki H; Suyama K; Yuruki H; Motohara T; Chiyonaga S; Akahoshi S
Anticancer Res; 2019 Dec; 39(12):6895-6901. PubMed ID: 31810959
[TBL] [Abstract][Full Text] [Related]
8. A case of hepatocellular carcinoma with pseudoaneurysm formation upon lenvatinib administration.
Yano R; Hirooka M; Nakamura Y; Imai Y; Koizumi Y; Watanabe T; Yoshida O; Tokumoto Y; Abe M; Hiasa Y
Clin J Gastroenterol; 2024 Apr; 17(2):319-326. PubMed ID: 38281290
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma.
Ikeda A; Aoki K; Kawamura M; Yamaguchi D; Kokuryu H
Intern Med; 2021; 60(3):403-407. PubMed ID: 33518611
[TBL] [Abstract][Full Text] [Related]
10. Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt.
Namba M; Kawaoka T; Aikata H; Kodama K; Uchikawa S; Ohya K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Imamura M; Baba Y; Awai K; Chayama K
Clin J Gastroenterol; 2019 Aug; 12(4):341-346. PubMed ID: 30706429
[TBL] [Abstract][Full Text] [Related]
11. Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma.
Hirooka M; Ochi H; Hiraoka A; Koizumi Y; Matsuura B; Joko K; Michitaka K; Abe M; Hiasa Y
Intern Med; 2019 Mar; 58(6):791-795. PubMed ID: 30333428
[TBL] [Abstract][Full Text] [Related]
12. Pneumothorax during lenvatinib treatment for hepatocellular carcinoma with lung metastasis.
Kawanishi Y; Kuwahara M; Utsunomiya M; Ishida N; Ishikawa Y; Hiroi M; Akimori T
Clin J Gastroenterol; 2021 Feb; 14(1):288-292. PubMed ID: 33108567
[TBL] [Abstract][Full Text] [Related]
13. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib.
Ikeda M; Kobayashi M; Tahara M; Kaneko S
Expert Opin Drug Saf; 2018 Nov; 17(11):1095-1105. PubMed ID: 30264594
[TBL] [Abstract][Full Text] [Related]
14. Destructive thyroiditis presenting as thyrotoxicosis followed by hypothyroidism during lenvatinib therapy for hepatocellular carcinoma.
Suoh M; Fujii H; Nagata Y; Kotani K; Hagihara A; Enomoto M; Tamori A; Inaba M; Kawada N
Clin J Gastroenterol; 2020 Oct; 13(5):860-866. PubMed ID: 32128670
[TBL] [Abstract][Full Text] [Related]
15. Temporary placement of a covered duodenal stent can avoid riskier anterograde biliary drainage when ERCP for obstructive jaundice fails due to duodenal invasion.
Goutorbe F; Rouquette O; Mulliez A; Scanzi J; Goutte M; Dapoigny M; Abergel A; Poincloux L
Surg Endosc; 2017 Feb; 31(2):625-631. PubMed ID: 27324333
[TBL] [Abstract][Full Text] [Related]
16. Severe skin ulcer caused by taking lenvatinib after proton beam therapy.
Iwasa T; Adachi S; Ogiso H; Takada E; Mabuchi M; Suzuki Y; Yamauchi O; Saito K; Iwashita T; Ogino H; Shimizu M
Clin J Gastroenterol; 2023 Aug; 16(4):588-592. PubMed ID: 37147555
[TBL] [Abstract][Full Text] [Related]
17. Long-term complete response to lenvatinib in a patient with unresectable hepatocellular carcinoma.
Ishizaki M; Kaibori M; Matsushima H; Kosaka H; Matsui K; Sekimoto M
Clin J Gastroenterol; 2021 Dec; 14(6):1700-1705. PubMed ID: 34480729
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
19. Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy.
Ohya K; Kawaoka T; Namba M; Uchikawa S; Kodama K; Morio K; Nakahara T; Murakami E; Hiramatsu A; Tsuge M; Yamauchi M; Imamura M; Chayama K; Aikata H
Sci Rep; 2019 Aug; 9(1):12101. PubMed ID: 31431642
[TBL] [Abstract][Full Text] [Related]
20. Reduction in Tumor Stain at 2 Weeks after Treatment Initiation Is a Predictor of the Efficacy of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma.
Kunimoto H; Shakado S; Tanaka T; Takata K; Yamauchi R; Fukuda H; Tsuchiya N; Yokoyama K; Morihara D; Takeyama Y; Hirai F; Sakisaka S
Oncology; 2020; 98(11):779-786. PubMed ID: 32877911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
